MedTrace Logo

Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus

NCT05446961 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2022-07-07

No results posted yet for this study

Summary

The purpose of the study is to assess safety and efficacy of Carnipure tartrate (L-Carnitine and L-tartaric acid - LCLT) supplementation for SARS-Cov-2 infection

Conditions

  • COVID-19 Virus Infection

Interventions

DIETARY_SUPPLEMENT

LCLT : 68% elemental L-carnitine and 32 % Tartric acid

3 g orally capsules

DRUG

Placebo

orally capsules

Sponsors & Collaborators

  • Hospital Espanhol

    collaborator NETWORK

  • SENAI CIMATEC

    lead OTHER

Principal Investigators

  • Roberto Badaró, Ph.D · SENAI CIMATEC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-09-01
Completion
2022-02-03

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05446961 on ClinicalTrials.gov